Evidence map›Paper›PMID 37004642›Full record

ArticleAdvances in therapy2023

A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".

Afisi S Ismaila, Katrin Haeussler, Mia Malmenäs, Raj Sharma, Chris Compton, Claus F Vogelmeier, MeiLan K Han, David M G Halpin

Open access · hybridAbstract readLetterCommentNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 5 countries.

Afisi S IsmailaValue Evidence and Outcomes, GSK, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA. afisi.s.ismaila@gsk.com.
Katrin HaeusslerICON Health Economics, ICON Plc., Munich, Germany.
Mia MalmenäsICON Health Economics, ICON Plc., Stockholm, Sweden.
Raj SharmaValue Evidence and Outcomes, R&D Global Medical, GSK, Brentford, UK.
Chris ComptonValue Evidence and Outcomes, R&D Global Medical, GSK, Brentford, UK.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.
MeiLan K HanDivision of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA.
David M G HalpinUniversity of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Health Economics and Outcomes Research (United Kingdom) · GBGerman Center for Lung Research · DESouth College · USUniversity of Exeter · GBUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AndrostadienesPulmonary Disease, Chronic ObstructiveAdministration, InhalationBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug CombinationsFluticasoneHumansQuinuclidinesAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug CombinationsFluticasonefluticasone furoateGSK573719QuinuclidinesvilanterolCOPDFixed-effects modelFluticasone furoate/umeclidinium/vilanterolHeterogeneityIndirect treatment comparisonNetwork meta-analysisRandom effects modelTriple therapy

Identifiers

PMID37004642
PMCPMC10129919
OpenAlexW4362507047

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.